Xenetic Biosciences (XBIO) Gross Profit (2011 - 2017)

Xenetic Biosciences' (XBIO) quarterly Gross Profit came in at -$12028.0 in Q3 2017, down 140.79% on a QoQ basis from $29485.0 in Q2 2013.

Xenetic Biosciences (XBIO) Gross Profit (2011 - 2017) Analysis & Trends

Xenetic Biosciences (XBIO) has 4 years of Gross Profit data on file, last reported at -$12028.0 in Q3 2017.

Quarterly Gross Profit changed N/A year-over-year to -$12028.0 in Q3 2017, while the trailing twelve-month figure through Sep 2018 was -$12028.0 (down 168.9% YoY) and the FY2013 annual result came in at $1.0 million, up 301.99% from the prior year.
Gross Profit declined to -$12028.0 in Q3 2017, from $29485.0 in the prior quarter.
In the past five years, Gross Profit ranged from a high of $29485.0 in Q2 2013 to a low of -$12028.0 in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Xenetic Biosciences	8.01 Mn	1.54 Mn	-

Download Data